09:41 AM EST - Oncolytics Biotech Inc : Announces advances in key pancreatic and anal cancer Trials, strengthening the pipeline in 2025. Regulatory progress in pancreatic cancer and recent clinical data presentations in two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, highlight pelareorep's potential impact across a range of tumors. Highlights two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study and the recent presentation of new efficacy and safety data at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in late January. Oncolytics Biotech Inc
shares T.ONC are trading unchanged at $1.07.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONC%3ACA&qmodStoryID=7901211951263730
